Abstract
Background Mycobacterium tuberculosis (Mtb) infection is inferred from positive results of T-cell immune conversion assays measuring Mtb-specific interferon gamma production or tuberculin skin test (TST) reactivity. Certain exposed individuals, termed resisters or early clearers, do not display T-cell immune conversion in these assays. Here we report a hitherto unknown extreme form of this phenotype: HIV-1-infected persistently TB, tuberculin and IGRA negative (HITTIN).
Methods A community-based case-control design was used to systematically screen and identify HIV-1-infected persons (aged 35-60 years) who met stringent study criteria, and follow up for repeat IGRA and TST testing. Participants had no history of TB despite living in TB hyper-endemic environments in Cape Town, South Africa with a provincial incidence of 681/100,000. Mtb-specific antibodies were measured using ELISA and Luminex.
Findings We identified 48/286(17%) individuals who tested persistently negative for Mtb-specific T-cell immunoreactivity (three negative Quantiferon results and one TST = 0mm) over 206±154 days on average. Of these, 97·2% had documented CD4 counts<200 prior to antiretroviral therapy (ART). They had received ART for 7·0±3·0 years with a latest CD4 count of 505·8±191·4 cells/mm3. All HITTIN sent for further antibody testing (n=38) displayed Mtb-specific antibody titres.
Interpretation Immune reconstituted HIV-infected persons can be persistently non-immunoreactive to Mtb, yet develop species-specific antibody responses. Exposure is evidenced by Mtb-specific antibody titers. Identifying individuals displaying such extreme resistance to T-cell immune conversion indicates the importance of early events of TB pathophysiology in the context of HIV-infection that so far have received only scant attention.
Funding Funding provided by National Institutes of Health [1R01AI124349-01].
Competing Interest Statement
Declaration of Interests Dr. Hoal reports grants from National Institutes of Health, during the conduct of the study. Dr. Möller reports grants from National Research Foundation, South Africa, during the conduct of the study. Dr. Schurr and Dr. Orlova reports grants from NIH, grants from CIHR, during the conduct of the study. Dr. Kroon reports grants from National Institutes of Health, other from European and Developing Countries Clinical Trials Partnership, other from South African Medical Research Council, during the conduct of the study. Dr. Alter reports other from Seromyx Systems Inc, outside the submitted work. Dr. Wilkinson reports grants from Wellcome, grants from National Institutes of Health, grants from European and Developing Countries Clinical Trials Partnership, grants from Foundation for the National Institutes of Health, grants from Cancer Research UK, grants from UK Research and Innovation, during the conduct of the study. Dr. Walzl reports other from Vakzien Projekt Managment and Serum Institute of India, outside the submitted work.
Funding Statement
This work was supported by the National Institutes of Health [1R01AI124349-01]. This research was partially funded by the South African government through the South African Medical Research Council (SAMRC) and supported by the National Research Foundation of South Africa. The content is solely the responsibility of the authors and does not necessarily represent the official views of the SAMRC. ES is supported by a Foundation grant from the Canadian Institutes of Health Research [FDN-143332]. RJW receives funding from the Francis Crick Institute, which is supported by United Kingdom Research and Innovation [FC0010218], Cancer Research UK [FC0010218], and Wellcome [FC0010218]. RJW is also supported by Wellcome [104803, 203135] and the National Institutes of Health [U19AI111276]. EEK is supported through funding by the SAMRC through its Division of Research Capacity Development under the Clinician Researcher Development PHD Scholarship Programme. EEK is also supported by a Career Development Fellowship [TMA2018CDF-2353-NeutroTB] awarded by The European and Developing Countries Clinical Trials Partnership.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Health Research Ethics Committee (HREC) of Stellenbosch University [N16/03/033 and N16/03/033A] and the Faculty of Health Sciences Human Research Ethics Committee of the University of Cape Town [HREC 755/2016 and 702/2017]. Additional approval was obtained from the City of Cape Town and Western Cape government for access to the relevant clinics.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from the corresponding author, Dr. Möller, upon reasonable request.
